Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06971913
PHASE2
Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia
Sponsor: Peking University People's Hospital
View on ClinicalTrials.gov
Summary
This clinical trial will assess the efficacy and safety of low-dose interleukin-2 (IL-2) treatment in systemic lupus erythematosus (SLE) complicated with cytomegalovirus (CMV) viremia.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-05-20
Completion Date
2025-12-30
Last Updated
2025-05-14
Healthy Volunteers
No
Conditions
Interventions
DRUG
Interleukin-2 (IL-2)
Low-dose IL-2 at 1MIU will be administered subcutaneously every other day from baseline to CMV negativity.
DRUG
Ganciclovir (GCV)
Ganciclovir injection will be administrated intravenously at a dose of 5mg/kg per day.
Locations (1)
Peking University People's Hospital
Beijing, Bejing, China